177 related articles for article (PubMed ID: 25082536)
1. Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma.
Baron Toaldo M; Salvatore V; Marinelli S; Palamà C; Milazzo M; Croci L; Venerandi L; Cipone M; Bolondi L; Piscaglia F
Mol Imaging Biol; 2015 Feb; 17(1):29-37. PubMed ID: 25082536
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma.
Marinelli S; Salvatore V; Baron Toaldo M; Milazzo M; Croci L; Venerandi L; Pecorelli A; Palamà C; Diana A; Bolondi L; Piscaglia F
BMC Cancer; 2014 Jun; 14():403. PubMed ID: 24902850
[TBL] [Abstract][Full Text] [Related]
3. Quantification of dynamic contrast-enhanced ultrasound in HCC: prediction of response to a new combination therapy of sorafenib and panobinostat in advanced hepatocellular carcinoma.
Knieling F; Waldner MJ; Goertz RS; Strobel D
BMJ Case Rep; 2012 Dec; 2012():. PubMed ID: 23257272
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion-weighted imaging in an orthotopic hepatocellular carcinoma xenograft model.
Yang SH; Lin J; Lu F; Han ZH; Fu CX; Lv P; Liu H; Gao DM
J Magn Reson Imaging; 2017 Jan; 45(1):270-280. PubMed ID: 27299302
[TBL] [Abstract][Full Text] [Related]
5. Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography.
Moschouris H; Malagari K; Gkoutzios P; Kalokairinou M; Stamatiou K; Chatzimichail K; Kornezos I; Karagiannis E; Kiltenis M; Papadaki MG
Med Ultrason; 2012 Jun; 14(2):87-94. PubMed ID: 22675707
[TBL] [Abstract][Full Text] [Related]
6. Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.
Zocco MA; Garcovich M; Lupascu A; Di Stasio E; Roccarina D; Annicchiarico BE; Riccardi L; Ainora ME; Ponziani F; Caracciolo G; Rapaccini GL; Landolfi R; Siciliano M; Pompili M; Gasbarrini A
J Hepatol; 2013 Nov; 59(5):1014-21. PubMed ID: 23811306
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study.
Shiozawa K; Watanabe M; Kikuchi Y; Kudo T; Maruyama K; Sumino Y
World J Gastroenterol; 2012 Oct; 18(40):5753-8. PubMed ID: 23155317
[TBL] [Abstract][Full Text] [Related]
8. Quantification in molecular ultrasound imaging: a comparative study in mice between healthy liver and a human hepatocellular carcinoma xenograft.
Sugimoto K; Moriyasu F; Negishi Y; Hamano N; Oshiro H; Rognin NG; Yoshida T; Kamiyama N; Aramaki Y; Imai Y
J Ultrasound Med; 2012 Dec; 31(12):1909-16. PubMed ID: 23197543
[TBL] [Abstract][Full Text] [Related]
9. Early response to anti-tumoral treatment in hepatocellular carcinoma--can quantitative contrast-enhanced ultrasound predict outcome?
Knieling F; Waldner MJ; Goertz RS; Zopf S; Wildner D; Neurath MF; Bernatik T; Strobel D
Ultraschall Med; 2013 Feb; 34(1):38-46. PubMed ID: 23258770
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.
Sugimoto K; Moriyasu F; Saito K; Rognin N; Kamiyama N; Furuichi Y; Imai Y
Liver Int; 2013 Apr; 33(4):605-15. PubMed ID: 23305331
[TBL] [Abstract][Full Text] [Related]
11. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
Scartozzi M; Faloppi L; Svegliati Baroni G; Loretelli C; Piscaglia F; Iavarone M; Toniutto P; Fava G; De Minicis S; Mandolesi A; Bianconi M; Giampieri R; Granito A; Facchetti F; Bitetto D; Marinelli S; Venerandi L; Vavassori S; Gemini S; D'Errico A; Colombo M; Bolondi L; Bearzi I; Benedetti A; Cascinu S
Int J Cancer; 2014 Sep; 135(5):1247-56. PubMed ID: 24510746
[TBL] [Abstract][Full Text] [Related]
12. [Value of ultrasound-targeted vascular endothelial growth factor receptor-2 in non-invasive monitoring of anti-angiogenic response in nude mice with subcutaneous xenograft model].
Wang L; Lu YH; Wang TY
Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):856-860. PubMed ID: 33113627
[No Abstract] [Full Text] [Related]
13. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J
Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089
[TBL] [Abstract][Full Text] [Related]
14. Squamous Cell Carcinoma Xenografts: Use of VEGFR2-targeted Microbubbles for Combined Functional and Molecular US to Monitor Antiangiogenic Therapy Effects.
Baetke SC; Rix A; Tranquart F; Schneider R; Lammers T; Kiessling F; Lederle W
Radiology; 2016 Feb; 278(2):430-40. PubMed ID: 26313618
[TBL] [Abstract][Full Text] [Related]
15. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts.
Tran A; Koh TS; Prawira A; Ho RZW; Le TBU; Vu TC; Hartano S; Teo XQ; Chen WC; Lee P; Thng CH; Huynh H
Mol Imaging Biol; 2021 Feb; 23(1):70-83. PubMed ID: 32909245
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
Liu LP; Ho RL; Chen GG; Lai PB
Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
[TBL] [Abstract][Full Text] [Related]
17. Ultrasound Molecular Imaging With BR55, a Predictive Tool of Antiangiogenic Treatment Efficacy in a Chemo-Induced Mammary Tumor Model.
Helbert A; Von Wronski M; Colevret D; Botteron C; Padilla F; Bettinger T; Tardy I; Hyvelin JM
Invest Radiol; 2020 Oct; 55(10):657-665. PubMed ID: 32229739
[TBL] [Abstract][Full Text] [Related]
18. Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model.
Qiu YQ; Zhou J; Kang XS; Ding LM; Yu W; Tan FL; Deng DF
Sci Rep; 2014 Mar; 4():4324. PubMed ID: 24632756
[TBL] [Abstract][Full Text] [Related]
19. Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging.
Liu S; Du Y; Ma H; Liang Q; Zhu X; Tian J
Cancer Lett; 2019 Jul; 453():74-83. PubMed ID: 30928380
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models.
Zhu XD; Sun HC; Xu HX; Kong LQ; Chai ZT; Lu L; Zhang JB; Gao DM; Wang WQ; Zhang W; Zhuang PY; Wu WZ; Wang L; Tang ZY
Angiogenesis; 2013 Oct; 16(4):809-20. PubMed ID: 23716000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
